Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at [email protected] Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Sun Pharma Seals Rs 97,500 Crore Organon Acquisition Deal

Sun Pharma discontinues development of skin disease drug after trials failure

Written By Ruchika Sharma4 Jun 2025 12:27 PM IST

Mumbai: Sun Pharmaceutical Industries Limited has announced the discontinuation of two clinical trials evaluating SCD-044, a novel, orally...

Teen Girl Dies After Injection at Khargone Clinic, Family Alleges Negligence

USFDA greenlights Gland Pharma BP injection in adults with septic shock

Written By Ruchika Sharma4 Jun 2025 11:30 AM IST

Hyderabad: Gland Pharma Limited, a generic injectable & ophthalmicfocused pharmaceutical company, has announced that the company has...

CDSCO Panel Accepts Glenmarks Apremilast Trial Report, Seeks 2-Year PSUR Data

Full dose escalation data show favorable safety profile of ISB 2001 for Multiple Myeloma: Ichnos Glenmark Innovation

Written By Ruchika Sharma3 Jun 2025 5:47 PM IST

New York: Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics...

Quadria Capital-Led Consortium Eyes Majority Stake in Samarth Lifesciences at Rs 4,500 Cr Valuation

Sanofi to acquire Blueprint Medicines for up to USD 9.5 billion

Written By Ruchika Sharma3 Jun 2025 3:23 PM IST

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis...

NPPA Finally Allows GSK to Discontinue Grisovin FP

GSK Linerixibat application for cholestatic pruritus in primary biliary cholangitis patients under USFDA review

Written By Ruchika Sharma3 Jun 2025 2:15 PM IST

London: GSK plc has announced the New Drug Application (NDA) for linerixibat, an investigational targeted inhibitor of the ileal bile...

Biocon Receives 5 USFDA Observations at Bengaluru Biosimilars Site

CDSCO approves Biocon diabetes drug Liraglutide

Written By Ruchika Sharma3 Jun 2025 11:51 AM IST

Liraglutide is a synthetic analog of GLP-1 peptide and is administered as a once-daily injection.

Alembic Pharma gets four USFDA observations for Panelav facility

Written By Ruchika Sharma2 Jun 2025 3:03 PM IST

Vadodara: Alembic Pharma has announced that the United States Food and Drug Administration (US FDA) has issued four observations after an...

Cipla appoints Prabhakaran Balakrishnan Nair as Global Chief Manufacturing Officer

Written By Ruchika Sharma2 Jun 2025 2:40 PM IST

Mumbai: Cipla has announced the appointment of Prabhakaran Balakrishnan Nair, presently working as Chief of Quality - Indore plant, as Senior...

Palamur Biosciences Faces USFDA Warning for Multiple GLP Compliance Failures

Zydus Lifesciences Rifaximin Tablets bags USFDA tentative nod for irritable bowel syndrome with diarrhoea

Written By Ruchika Sharma2 Jun 2025 12:58 PM IST

Ahmedabad: Pharma major, Zydus Lifesciences Limited, has received tentative approval from the United States Food and Drug...

Around 5,000 Small Pharma Units at Risk as Centre Enforces Tougher GMP Norms

USFDA successfully completes inspection at Piramal Pharma Canada facility

Written By Ruchika Sharma2 Jun 2025 12:00 PM IST

Mumbai: Piramal Pharma Limited has announced that the US Food and Drug Administration (USFDA) has successfully completed inspection...

Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron

Written By Ruchika Sharma1 Jun 2025 3:00 PM IST

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic...

Merck, Daiichi Sankyo withdraw US appication for patritumab deruxtecan for advanced or metastatic EGFR-mutated non-small cell lung cancer

Written By Ruchika Sharma31 May 2025 3:18 PM IST

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics License Application...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok